Insulin resistance and metabolic syndrome: Is Helicobacter pylori criminal?

Minerva Gastroenterologica e Dietologica

Volumn 57, Issue 4, 2011, Pages 379-385

  Eshraghian, A ^a   Eshraghian, H ^a   Ranjbar Omrani, G ^b  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Atherosclerosis; Helicobacter pylori; Insulin resistance; Metabolic syndrome X

Indexed keywords

FETUIN; GHRELIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1;

DISEASE ASSOCIATION; DRUG MECHANISM; ERADICATION THERAPY; HELICOBACTER INFECTION; HORMONE ACTION; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; METABOLIC SYNDROME X; NONHUMAN; PATHOPHYSIOLOGY; PREVALENCE; PROTEIN FUNCTION; REVIEW;

HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X;

EID: 84856526305     PISSN: 00264776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Suerbaum S, Michetti P. Helicobacter Pylori infection. N Engl J Med 2002;3:1175-86.
2. Hoffmeister A, Rothenbacher D, Bode G, Persson K, März W, Nauck MA et al. Current infection with Helicobacter pylori but not seropositivity to Chlamydia pneumoniae or Cytomegalovirus is associated with an atherogenic, modified lipid profile. Arterioscler Thromb Vasc Biol 2001;21:427-32. (Pubitemid 32199126)
3. Stasi R, Sarpatwari A, Segal JB, Osborn J, Evangelista ML, Cooper N et al. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systemic review. Blood 2009;113:1231-40.
4. Mendall M, Goggin M, Molineaux N, Levy J, Toosy T, Strachan D et al. Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J 1994;71:437-9. (Pubitemid 2068912)
5. Gunji T, Matsuhashi N, Sato H, Fujibayashi K, Okumura M, Sasabe N et al. Helicobacter Pylori infection is significantly associated with metabolic syndrome in the Japanese population. Am J Gastroenterol 2008;103:3005-10.
6. Stettin D, Waldmann A, Strohle A, Hahn A. Association between Helicobacter pylori infection, C-reactive protein and status of B vitamis. Adv Med Sci 2008;53:205-13.
7. Kaneko H, Konagaya T, Kusugami K. Helicobacter pylori and gut hormones. J Gastroenterol 2002;37:77-86. (Pubitemid 34223739)
8. Haffner SM, Miettinen H. Insulin resistance implications for type II diabetes mellitus and coronary heart disease. Am J Med 1997;103:152-62. (Pubitemid 27352120)
9. Beckman JA. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002;287:2570.
10. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III consensus report. Gut 2007;56:772-81. (Pubitemid 46854190)
11. Nabipour I, Vahdat K, Jafari SM, Pazoki R, Sanjdideh Z. The association of metabolic syndrome and Chlamydia pneumoniae, Helicobacter pylori, cytomegalovirus, and herpes simplex virus type 1: The Persian Gulf Healthy Heart Study. Cardiovasc Diabetol 2006;1:5:25.
12. Lutsey PL, Pankow JS, Bertoni AG, Szklo M, Folsom AR. Serologic evidence of infections and type 2 diabetes: the multi Ethnic study of atherosclerosis. Diabet Med 2009;26:149-52.
13. Oldenburg B, Diepersloot RJ, Hoekstra JB. High seroprevalence of Helicobacter pylori in diabetes mellitus patients. Dig Dis Sci 1996;41:458-61. (Pubitemid 26116401)
14. Marrollo M, Latella G, Melideo D, Storelli E, Iannarelli R, Stornelli P et al. Increased prevalence of Helicobacter pylori in patients with diabetes mellitus. Dig Liver Dis 2001;33:21-9. (Pubitemid 32186171)
15. Gulcelik NE, Kaya E, Demirbas B, Culha C, Koc G, Ozkaya M et al. Helicobacter pylori prevalence in diabetic patients and its relationship with dyspepsia and autonomic neuropathy. J Endocrinol Invest 2005;28:214-7. (Pubitemid 43162767)
16. Quadri R, Rossi C, Catalfamo E, Masoero G, Lombardo L, Delia Monica P et al. Helicobacter pylori infection in type 2 diabetic patients. Nutr Metab Cardiovasc Dis 2000;10:263-6.
17. Anastasios R, Goritsas C, Papamihail C, Trigidou R, Garzonis P, Ferti A. Helicobacter pylori infection in diabetic patients: prevalence and endoscopic findings. Eur J Intern Med 2002;13:376.
18. Demir M, Gokturk HS, Ozturk NA, Kulaksizoglu M, Serin E, Yilmaz U. Helicobacter pylori prevalence in diabetes mellitus patients with dyspeptic symptoms and its relationship to glycemic control and late complications. Dig Dis Sci 2008;53:2646-9.
19. Ko GT, Chan FK, Chan WB, Sung JJ, Tsoi CL, To KF et al. Helicobacter pylori infection in Chinese subjects with type 2 diabetes. Endocr Res 2001;27:171-7. (Pubitemid 32565586)
20. Aydemir S, Bayraktaroglu T, Sert M, Sokmen C, Atmaca H, Mungan G et al. The effect of Helicobacter pylori on insulin resistance. Dig Dis Sci 2005;50:2090-3. (Pubitemid 41504094)
21. Asian M, Horoz M, Nazligul Y, Bolukbas C, Bolukbas FF, Selek S et al. Insulin resistance in H pylori infection and its association with oxidative stress. World J Gastroenterol 2006;12:6865-8. (Pubitemid 44811411)
22. Ozdem S, Akcam M, Yilmaz A, Artan R. Insulin resistance in children with Helicobacter pylori infection. J Endocrinol Invest 2007;30:23640.
23. Eshraghian A, Hashemi SA, Hamidian Jahromi A, Eshraghian H, Masoompour SM, Davarpanah MA et al. Helicobacter pylori infection as a risk factor for insulin resistance. Dig Dis Sci 2009;54:1966-70.
24. Gunji T, Matsuhashi N, Sato H, Fujibayashi K, Okumura M, Sasabe N et al. Helicobacter pylori infection significantly increases insulin resistance in the asymptomatic Japanese population. Helicobacter 2009;14:144-50.
25. Gillum RF. Infection with Helicobacter pylori, coronary heart disease, cardiovascular risk factors, and systemic inflammation: the Third National Health and Nutrition Examination Survey. J Natl Med Assoc 2004;96:1470-6. (Pubitemid 39482993)
26. Gao XY, Kuang HY, Liu XM, Duan P, Yang Y, Ma ZB. Circulating ghrelin/obestatin ratio in subjects with Helicobacter pylori infection. Nutrition 2009;25:506-11.
27. So WY, Tong PC, Ko GT, Ma RC, Ozaki R, Kong AP et al. Low plasma adiponectin level, white blood cell count and Helicobacter pylori titre independently predict abnormal pancreatic beta-cell function. Diabetes Res Clin Pract 2009;86:89-95.
28. Park SH, Jeon WK, Kim SH, Kim HJ, Park DI, Cho YK et al. Helicobacter pylori eradication has no effect on metabolic and inflammatory parameters. J Natl Med Assoc 2005;97:508-13. (Pubitemid 40463581)
29. Longo-Mbenza B, Nkondi Nsenga J, Vangu Ngoma D. Prevention of the metabolic syndrome insulin resistance and the atherosclerotic diseases in Africans infected by Helicobacter pylori infection and treated by antibiotics. Int J Cardiol 2007;121:229-38. (Pubitemid 47469953)
30. Imai J, Yamada T, Saito T, Ishigaki Y, Hinokio Y, Kotake H et al. Eradication of insulin resistance. Lancet 2009;374:264.
31. Goldfi Ne AB, Moses AC. Syndromes of extreme insulin resistance. In: Kahn CR, Weir GC, King GL et al., editors. Joslin's diabetes mellitus. 14th ed. Philadelphia, PA: Lippincott, Williams, and Wilkins; 2005. p. 493-504.
32. Stasi R, Sarpatwari A, Segal JB, Osborn J, Evangelista ML, Cooper N et al. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systemic review. Blood 2009;113:1231-40.
33. Cicconi V, Carloni E, Franceschi F, Nocente R, Silveri NG, Manna R et al. Disappearance of antiphospholipid antibodies syndrome after Helicobacter pylori eradication. Am J Med 2001;111:163-4. (Pubitemid 32728416)
34. Zentilin P, Seriolo B, Dulbecco P, Caratto E, Iiritano E, Fasciolo D et al. Eradication of Helicobacter pylori may reduce disease severity in rheumatoid arthritis. Aliment Pharmacol Ther 2002;16:1291-9.
35. Manolakis AC, Tiaka EK, Kapsoritakis AN, Georgoulias P, Tsiopoulos F, Valotassiou V et al. Increased fetuin A levels in Helicobacter pylori infection: a missing link between H. pylori and insulin resistance? Diabetologica 2011;54:4724.
36. Gen R, Demir M, Ataseven H. Effect of Helicobacter pylori eradication on insulin resistance, serum lipids and low-grade inflammation. South Med J 2010;103:190-6.
37. Ferrannini E. Insulin resistance vs. insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. Endocr Rev 1998;19:477-90. (Pubitemid 29116377)
38. Ernst PB, Jin Y, Reyes VE, Crowe SE. The role of the local immune response in the pathogenesis of peptic ulcer formation. Scand J Gastroenterol 1994;29(Suppl 205):22-8. (Pubitemid 24381270)
39. Fan XG, Chua A, Fan XJ, Keeling PW. Increased gastric production of interleukin-8 and tumor necrosis factor in patients with Helicobacter pylori infection. J Clin Pathol 1995;48:133-6.
40. Ebrahimi A, Nabipour I, Vahdat K, Jafari SM, Fouladvand M, Assadi M et al. High sensitivity C-reactive protein is associated with the metabolic syndrome independent to viral and bacterial pathogen burden. Diabetes Res Clin Pract 2009;84:296-302.
41. Zhou MS, Schulman IH, Raij L. Vascular inflammation, insulin resistance, and endothelial dysfunction in salt-sensitive hypertension: role of nuclear factor kappa B activation. J Hypertens 2010;28:527-35.
42. Eshraghian A, Eshraghian H. Interventional studies to confirm association of Helicobacter pylori and insulin resistance: a winding road. South Med J 2010;103:1072.
43. Kebapcilar L, Sari I, Renkal AH, Alacacioglu A, Yuksel A, Ilhan E et al. The influence of Helicobacter pylori eradication on leptin, soluble CD40 ligand, oxidative stress and body composition in patients with peptic ulcer disease. Intern Med 2009;48:2055-9.
44. Eshraghian A, Eshraghian H. The Influence of Helicobacter pylori eradication on soluble CD40 ligand and oxidative stress: a step forward to prevent atherosclerosis. Intern Med 2010;49:877.
45. Colturi TJ, Unger RH, Feldman M. Role of circulating somatostatin in regulation of gastric acid secretion, gastrin release, and islet cell function. Studies in healthy subjects and duodenal ulcer patients. J Clin Invest 1984;74:417-23. (Pubitemid 14053988)
46. Rehfeld JF, Stadil F. The effect of gastrin on basal- and glucosestimulated insulin secretion in man. J Clin Invest 1973,52:1415-26.
47. Salles N, Menard A, Georges A, Salzmann M, de Ledinghen V, de Mascarel A et al. Effects of Helicobacter pylori infection on gut appetite peptide (leptin, ghrelin) expression in elderly inpatients. J Gerontol A Biol Sci Med Sci 2006;61:1144-50. (Pubitemid 46034464)
48. Lankarani KB, Moghadami M, Masoumpoor M, Geramizadeh B, Omrani GR. Serum leptin level in patients with functional dyspepsia. Dig Liver Dis 2004;36:717-21. (Pubitemid 41070592)
49. Nishi Y, Isomoto H, Uotani S, Wen CY, Shikuwa S, Ohnita K et al. Enhanced production of leptin in gastric fundic mucosa with Helicobacter pylori infection. World J Gastroenterol 2005;7:695-9. (Pubitemid 40220760)
50. Cohen B, Novick D, Rubinstein M. Modulation of insulin activities by leptin. Science 1996;274:1185-8. (Pubitemid 26389283)
51. Gauna C, Kiewiet RM, Janssen JA, van de Zande B, Delhanty PJ, Ghigo E et al. Unacylated ghrelin acts as a potent insulin secretagogue in glucose-stimulated conditions. Am J Physiol Endocrinol Metab 2007;293:E697-704. (Pubitemid 47358981)
52. Gonzalez-Rey E, Chorny A, Delgado M. Therapeutic action of ghrelin in a mouse model of colitis. Gastroenterology 2006;130:1707-20. (Pubitemid 43668852)
53. Kawashima J, Ohno S, Sakurada T, Takabayashi H, Kudo M, Ro S et al. Circulating acylated ghrelin level decreases in accordance with the extent of atrophic gastritis. J Gastroenterol 2009;44:1046-54.
54. Mathews ST, Rakhade S, Zhou X, Parker GC, Coscina DV, Grunberger G et al. Fetuinnullmice are protected against obesity and insulin resistance associated with aging. Biochem Biophys Res Commun 2006;350:437-43. (Pubitemid 44498655)
55. Stefan N, Hennige AM, Staiger H, Machann J, Schick F, Kröber SM et al. Alpha2- Heremans-Schmid glyco-protein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care 2006;29:853-7. (Pubitemid 44115306)
56. Ix JH, Wassel CL, Kanaya AM, Vittinghoff E, Johnson KC, Koster A et al. Fetuin-A and incident diabetes mellitus in older persons. JAMA 2008;300:182-8. (Pubitemid 351969302)
57. Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa K, Kitazawa R et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006;116:1494-505.
58. Kamei N, Tobe K, Suzuki R, Ohsugi M, Watanabe T, Kubota N et al Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J Biol Chem 2006;281:26602-14. (Pubitemid 44401869)
59. Di Gregorio GB, Yao-Borengasser A, Rasouli N, Varma V, Lu T, Miles LM et al Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by pioglitazone. Diabetes 2005;54:2305-13. (Pubitemid 41134256)
60. Futagami S, Hiratsuka T, Tatsuguchi A, Suzuki K, Kusunoki M, Shinji Y et al. Monocyte chemoattractant protein 1 (MCP-1) released from Helicobacter pylori stimulated gastric epithelial cells induces cyclooxygenase 2 expression and activation in T cells. Gut 2003;52:1257-64. (Pubitemid 37026456)
61. Mori N, Ueda A, Geleziunas R, Wada A, Hirayama T, Yoshimura T et al Induction of monocyte chemoattractant protein 1 by Helicobacter pylori involves NF-kappaB. Infect Immun 2001;69:1280-6. (Pubitemid 32187571)
62. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappa B. Nat Med 2005;11:183-90. (Pubitemid 40321354)
63. Csiszar A, Wang M, Lakatta EG, Ungvari Z. Inflammation and endothelial dysfunction during aging: role of NF-kappaB. J Appl Physiol 2008;105:1333-41.
64. Kim Do J, Park KS, Kim JH, Yang SH, Yoon JY, Han BG et al. Helicobacter pylori proinflammatory protein up-regulates NF-kappaB as a cell-translocating Ser/Thr kinase. Proc Natl Acad Sci U S A 2010;107:21418-23.